Use of Restraint and Seclusion in the Emergency Department
August 1st 2005Restraints and seclusion have been used for many years in emergency departments (EDs) and psychiatric emergency services (PESs), but anecdotal case reports and newspaper investigations as well as clinical advances have led to restrictions in their use.
Perspective on the Use of Seclusion and Restraint
August 1st 2005Dr Zun has done an excellent job of reviewing the many controversies and complexities that surround the use of mechanical and chemical restraint as well as seclusion. He also shows us how many unanswered questions there are about such interventions. For example, an insightful psychiatric resident once raised the question of which intervention was more restrictive and stigmatizing: seclusion or restraint?
Nature Versus Nurture: How Is Child Psychopathology Developed?
July 1st 2005In an attempt to reframe the either-or debate over the impact of genetics versus environment on emotional makeup, a panel convened at the American Psychoanalytic Association’s Winter 2005 Meeting in New York City. This article highlights studies presented at the meeting.
Managing Treatment-Resistant OCD
July 1st 2005Obsessive-compulsive disorder is a prevalent, disabling and chronic illness. Serotonin reuptake inhibitors are the first-line of treatment; however a large proportion of patients will have either a partial or nonresponse. This review outlines the strategies for treatment-resistant OCD, including augmentation agents, alternative monotherapies, intravenous strategies and newer nonpharmacologic somatic treatments under development.
Congress, Advocates Call for Stronger Teeth for FDA
July 1st 2005After the apparent failures of the U.S. Food and Drug Administration to discern cardiovascular effects of COX-2 inhibitors and suicidality in children receiving antidepressants, critics of the FDA say that the agency has failed to protect public health. Read what advocacy groups are saying and Congress is doing to change the FDA.
The Conceptualization and Role of Impulsivity: Bipolar Disorder and Substance Abuse
July 1st 2005Impulsive behaviors play an important role in both bipolar and substance abuse disorders. However, results of studies investigating this link are often ambiguous, in part, due to the multidimensional nature of the impulsivity construct and the fact that many studies use a single measurement technique. We describe a model of impulsivity characterized by three components: response initiation, response inhibition and consequence sensitivity. How these components differ from one another in terms of their use, behavioral theory and biological function is discussed, along with measurement techniques.
NIDA Responds to Escalating Prescription Drug Abuse
July 1st 2005Marijuana is the number one illegal drug of abuse in the United States; in second place is the nonmedical use of prescription medications such as pain relievers, tranquilizers, stimulants and sedatives. The National Institute on Drug Abuse is intensifying its research in understanding mechanisms that underlie the reinforcing, addictive and toxic properties of prescription medications, and developing medications with less abuse potential.
Second-Generation Antipsychotics and the Risk of Insulin Resistance, Dyslipidemia in Children
July 1st 2005Comparative data are emerging on the metabolic effects of the second-generation antipsychotics on adolescents and children. Data presented at national meetings is discussed. When using these medications, the risks and benefits need to be carefully weighed until more definitive information is available.
Neurology NewsfeatureNeurology Subspecialization Takes a Step Forward
July 1st 2005Subspecialization within the practice of neurology is now reality with the recent approvals of subspecialty designations for neuromuscular pathology, headache medicine, and neuro-oncology. The American Academy of Neurology (AAN) Committee on Neuromuscular Pathology sponsored the neuromuscular pathology membership application. Two associations--the AAN Headache and Facial Pain Section and the American Headache Society--sponsored the headache medicine application.
"Stubborn Optimism" Dominates the Landscape of ALS
July 1st 2005Animal models enable researchers to track amyotrophic lateral sclerosis (ALS) pathogenesis. Erik Storkebaum, MSc, and colleagues at the Center for Transgene Technology and Gene Therapy at Flanders Interuniversity, Leuven, Belgium, took several approaches to increase supply of the neuroprotective protein vascular endothelial growth factor (VEGF) in an animal model. "When administered to rats at 60 days, which is 1 month before symptoms, it delayed onset and prolonged survival by 22 days. When we gave VEGF at the age of disease onset, which more closely mimics the human situation, the treatment still prolonged life by an average of 10 days," Storkebaum reported at the Society for Neuroscience annual meeting in October 2004
Clinical Trials Appear Headed for More OpennessNeurology Newsfeature
July 1st 2005All clinical trial sponsors will be required to register all publicly and privately sponsored clinical trials with the existing government clinical trials registry, www.clinicaltrials.gov, before the first patient is enrolled in the trial.
New Spinal Cord Center Offers More Than Local Services
July 1st 2005Until recently, physicians assumed that any recovery from spinal cord injury (SCI) was limited to the first few months to a year after the injury occurred. In children, this window of opportunity for recovery could last about 2 years. Certainly, no one expected any significant recovery in any person with a chronic SCI or other condition that causes SCIs, such as a stroke, blood clots, or arteriovenous malformation affecting the spinal cord.
Adverse Effects of Antiepileptic Medications in Children: A Case Report and Review
July 1st 2005On physical examination, the patient appeared well, except for the obvious diffuse rash. Erythematous macules, papules, and patches covered his extremities, face, trunk, palms, and soles. His conjunctivae, mucous membranes, and joints were normal, as were the results of cardiac, pulmonary, abdominal, and neurologic examinations. Several anterior and posterior cervical lymph nodes (0.5 to 1 cm) were present bilaterally.
Mental Notes * newsworthy and useful
July 1st 2005The FDA approved on June 21 the prescribing of levetiracetam (Keppra, UCB Pharma) as an add-on treatment for partial-onset seizures in children 4 years or older who have epilepsy. The approval follows a randomized, double-blind, placebo-controlled trial conducted at 60 sites and involving 198 children aged 4 to 16 years